Antimicrobial Resistance Surveillance Market

Antimicrobial Resistance Surveillance Market by Solution (Kits, System, Surveillance Software, Service), Application (Clinical Diagnostics, Public Health Surveillance), End User (Hospitals, Clinics, Academic, Research Institutes) & Region - Global Forecast to 2028

Report Code: BT 8787 Sep, 2023, by marketsandmarkets.com

The global antimicrobial resistance (AMR) surveillance market was valued at $5.9 billion in 2023 and is projected to reach $7.7 billion by 2028, growing at a 5.6% CAGR. Key drivers include the rising prevalence of infections caused by drug-resistant pathogens such as MRSA, VRE, MDR-TB, and CRE. Innovations in diagnostics and government efforts to combat AMR further fuel market growth. Despite these drivers, high costs of diagnostic systems and complex regulatory frameworks present challenges. Emerging economies, especially in Asia-Pacific and Latin America, offer significant growth opportunities. The market includes solutions like diagnostic kits, systems, software, and services, with hospitals and clinics being the primary users. Key players include Luminex, Thermo Fisher Scientific, Cepheid, and Roche Diagnostics. North America dominates the market due to advanced healthcare infrastructure and high AMR prevalence.

Global Antimicrobial Resistance Surveillance Market Trends

Antimicrobial Resistance Surveillance Market

To know about the assumptions considered for the study, Request for Free Sample Report

Antimicrobial Resistance Surveillance Market

Antimicrobial Resistance Surveillance Market Dynamics

Driver: Growing prevalence of infections caused by drug-resistance pathogens

According to a published article by NCBI, within India, the incidence of VRE infections is on the rise, fluctuating between 1% and 8.7%. Our own investigation further demonstrates an escalating VRE infection rate in the bloodstream, climbing from 6.12% in 2018 to 19.2% in 2020. The growing number of epidemic outbreaks caused by drug-resistance pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), multi-drug-resistant Mycobacterium tuberculosis (MDR-TB), and carbapenem-resistant Enterobacteriaceae (CRE) gut bacteria is also propelling the demand for antimicrobial resistance surveillance solutions.

Restraint: High cost of antimicrobial resistance diagnostic systems/ kits

Antimicrobial resistance (AMR) exerts a substantial toll on economies. Beyond its human toll of mortality and disability, the protracted illnesses it causes lead to extended hospitalizations, heightened reliance on costlier pharmaceuticals, and financial hardships for affected individuals. Moreover, the pricing of AMR kits and instruments is positioned at a premium level. According to the NorthShore University Health System, the cost of reagents (at a volume of 29,200 tests per year) using automated systems is USD 165,856 per year as opposed to USD 43,508 per year using the disk diffusion method. Furthermore, the use of automated systems results in additional spending of USD 90,668 per year than that required for the semi-automated disk diffusion method.

Academic research laboratories generally cannot afford such systems as they have limited budgets. In addition, the maintenance costs and several other indirect expenses result in an overall increase in the total cost of ownership of these instruments. These factors hinder the mass adoption of antimicrobial resistance surveillance systems.

Opportunity: Growth opportunities in emerging economies

Emerging economies are expected to become a focal point for the growth of the ARS market. The Asia Pacific, Middle Eastern, and Latin American regions are relatively untapped markets for companies as compared to Europe and North America. Russia, India, China, Brazil, and South Africa are significant contributors to antibiotic adoption, accounting for 76% of the increase in antibiotic usage. The changes in antibiotic usage over the last decade have been exceptional, and this is mostly due to the advent of new illnesses. ~USD 3.3 million through the Russian Federation-funded FAO initiative was provided in 2019-20 for assisting national authorities in Armenia, Belarus, Kazakhstan, Kyrgyzstan, and Tajikistan in addressing the dangers presented by antibiotic-resistant microbes in agriculture and food systems.

Challenge: Complex Regulatory Frameworks

Among the major challenges faced by the antimicrobial resistance surveillance market is the time lag between establishing clinical breakpoints, approval of new antimicrobial agents, and the inclusion of these agents in antimicrobial susceptibility testing. Clinical breakpoints are defined as the concentration of an antibiotic that enables the interpretation of AST to define isolates as susceptible, intermediate, or resistant, thereby predicting the efficacy of an antimicrobial drug in treating a clinical disease. The FDA establishes these breakpoints when drug manufacturers submit individual new drug applications or when device manufacturers submit requests to revise the breakpoints.

Antimicrobial Resistance Surveillance Market Ecosystem Map

Antimicrobial Resistance Surveillance Market Ecosystem

In 2023, the diagnostic kits segment is projected to account for the largest share of the antimicrobial resistance surveillance industry

By solutions, the global antimicrobial resistance surveillance market has been segmented into diagnostic kits, diagnostic systems, surveillance software, and services. In 2023, the diagnostic kits segment is estimated to command the largest share of the global antimicrobial resistance surveillance market. The large share of this segment can primarily be attributed to the increasing demand for rapid and accurate diagnostics for antimicrobial resistance. Diagnostic kits are used to detect the presence of antimicrobial-resistant bacteria in clinical samples, such as blood, urine, and respiratory secretions.

Clinical Diagnostics is projected to account for the largest share of the antimicrobial resistance surveillance industry in 2023

By application, the global antimicrobial resistance surveillance market has been segmented into clinical diagnostics, public health surveillance, and other applications . In 2023, the clinical diagnostics segment is expected to command the largest share of the global antimicrobial resistance surveillance market. The growth in this segment can be attributed to factors such as increasing prevalence of antimicrobial resistance, need to improve patient outcomes, used to determine the susceptibility of bacteria to different antimicrobial agents and this information is essential for healthcare providers to make informed decisions about the treatment of patients with antimicrobial-resistant infections.

By end user, hospitals and clinics accounted for the largest share of the antimicrobial resistance surveillance industry

By end users, the global antimicrobial resistance surveillance market has been segmented into hospitals & clinics, research and academic institutes, and others. In 2023, the hospitals & clinics segment is expected to command the largest share of the global antimicrobial resistance surveillance market.The large share of this segment can be attributed to the fact that because they are the primary settings where antimicrobial-resistant infections occur and they are required to conduct antimicrobial resistance surveillance.

By region, North America is projected to account for the largest share of the antimicrobial resistance surveillance industry

By region the global antimicrobial resistance surveillance segmented into—North America, Europe, Asia Pacific, Latin America, and Middle East Africa. In 2023, North American antimicrobial resistance surveillance market is expected to account for the largest share of the global antimicrobial resistance surveillance market. This can be attributed to the presence of leading market players, highest prevalence of antimicrobial resistance, and strong regulatory environment.

Antimicrobial Resistance Surveillance Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in this market are Luminex Corporation (US), Thermo Fisher Scientific (US), BioSpace (US), Cepheid (US), Accelerate Diagnostics, Inc. (US), Liofilchem S.r.l. (Italy), Becton, Dickinson and Company (US), Biomerieux (France), Bruker (US), Danaher (US), Merck KgaA (Germany), Bio-Rad (US), Qiagen (Germany), Abbott Laboratories (US), Roche Diagnostics (Switzerland), OpGen, Inc. (US), Wolters Kluwer N.V. (US), Lumed (US), Alifax S.r.l. (Italy), and Bioanalyse (Turkey).

Scope of the Antimicrobial Resistance Surveillance Industry:

Report Metric

Details

Market Revenue in 2023

$5.9 billion

Estimated Value by 2028

$7.7 billion

Revenue Rate

Poised to grow at a CAGR of 5.6%

Market Driver

Growing prevalence of infections caused by drug-resistance pathogens

Market Opportunity

Growth opportunities in emerging economies

The study categories the antimicrobial resistance surveillance Market to forecast revenue and analyze trends in each of the following submarkets:

By Solution

  • Diagnostic kits
  • Diagnostic systems
  • Surveillance software
  • Services

By Application

  • Clinical Diagnostics
  • Public Health Surveillance
  • Other Applications

By End User

  • Hospitals & Clinics
  • Research & Academic Institutes
  • Others

By Region

  • North America
    • US
    • Canada
  • Europe
    • France
    • Spain
    • UK
    • Italy
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 27)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY 
          TABLE 1 STANDARD CURRENCY CONVERSION RATES
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 RECESSION IMPACT ON ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET 
 
2 RESEARCH METHODOLOGY (Page No. - 31)
    2.1 RESEARCH APPROACH 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 2 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Insights from primary experts
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
          FIGURE 5 BOTTOM-UP APPROACH
          FIGURE 6 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET (2023–2028)
          FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    2.3 APPROACH USED TO DETERMINE IMPACT OF ECONOMIC RECESSION 
    2.4 MARKET BREAKDOWN & DATA TRIANGULATION 
          FIGURE 8 MARKET DATA TRIANGULATION METHODOLOGY
    2.5 MARKET SHARE ANALYSIS 
    2.6 STUDY ASSUMPTIONS 
    2.7 RESEARCH LIMITATIONS 
           2.7.1 METHODOLOGY-RELATED LIMITATIONS
    2.8 RISK ASSESSMENT 
          TABLE 2 RISK ASSESSMENT: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET
 
3 EXECUTIVE SUMMARY (Page No. - 42)
    FIGURE 9 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION,  2023 VS. 2028 (USD MILLION)
    FIGURE 10 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION,  2023 VS. 2028 (USD MILLION)
    FIGURE 11 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER,  2023 VS. 2028 (USD MILLION)
    FIGURE 12 GEOGRAPHICAL SNAPSHOT OF ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET
 
4 PREMIUM INSIGHTS (Page No. - 45)
    4.1 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET OVERVIEW 
          FIGURE 13 GROWING PREVALENCE OF INFECTIONS CAUSED BY DRUG-RESISTANT PATHOGENS TO DRIVE MARKET GROWTH
    4.2 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY REGION 
          FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD (2023–2028)
    4.3 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION AND COUNTRY (2022) 
          FIGURE 15 CLINICAL DIAGNOSTICS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET IN 2022
    4.4 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: GEOGRAPHIC MIX 
          FIGURE 16 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
    4.5 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET:  DEVELOPED VS. EMERGING ECONOMIES 
          FIGURE 17 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 50)
    5.1 INTRODUCTION 
          FIGURE 18 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.1.1 DRIVERS
                    5.1.1.1 Growing prevalence of infections caused by drug-resistant pathogens
                    5.1.1.2 Innovations in diagnostic technologies
                    5.1.1.3 Growing government initiatives to combat antimicrobial-resistant species
                    5.1.1.4 Emergence of multi-drug resistance due to drug abuse
           5.1.2 RESTRAINTS
                    5.1.2.1 High cost of antimicrobial resistance diagnostic systems/kits
           5.1.3 OPPORTUNITIES
                    5.1.3.1 Growth opportunities in emerging economies
                    5.1.3.2 Awareness initiatives for antimicrobial resistance and control
           5.1.4 CHALLENGES
                    5.1.4.1 Complex regulatory frameworks
    5.2 TECHNOLOGY ANALYSIS 
           5.2.1 REAL-TIME SURVEILLANCE PLATFORMS
           5.2.2 CRISPR-CAS SYSTEMS
           5.2.3 AI-POWERED MOBILE APPLICATIONS
    5.3 PRICING ANALYSIS 
           5.3.1 AVERAGE SELLING PRICE TREND OF PRODUCTS OFFERED BY KEY PLAYERS
                    FIGURE 19 AVERAGE SELLING PRICE TREND OF PRODUCTS OFFERED BY KEY PLAYERS
                    TABLE 3 AVERAGE SELLING PRICE TREND OF PRODUCTS OFFERED BY KEY PLAYERS
           5.3.2 AVERAGE SELLING PRICE TREND, BY REGION
                    TABLE 4 AVERAGE SELLING PRICE OF ANTIMICROBIAL RESISTANCE SURVEILLANCE SOLUTIONS, BY REGION
    5.4 VALUE CHAIN ANALYSIS 
          FIGURE 20 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: VALUE CHAIN ANALYSIS
    5.5 SUPPLY CHAIN ANALYSIS 
          FIGURE 21 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: SUPPLY CHAIN ANALYSIS
    5.6 ECOSYSTEM ANALYSIS 
          FIGURE 22 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: ECOSYSTEM MARKET MAP
    5.7 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 5 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.7.1 THREAT OF NEW ENTRANTS
           5.7.2 THREAT OF SUBSTITUTES
           5.7.3 BARGAINING POWER OF BUYERS
           5.7.4 BARGAINING POWER OF SUPPLIERS
           5.7.5 INTENSITY OF COMPETITIVE RIVALRY
    5.8 TARIFF AND REGULATORY ANALYSIS 
           5.8.1 TARIFF FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE DIAGNOSTIC SYSTEMS
                    TABLE 6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.8.2 REGULATORY ANALYSIS
                    5.8.2.1 North America
                               5.8.2.1.1 US
                                               TABLE 7 US FDA: MEDICAL DEVICE CLASSIFICATION
                                               TABLE 8 US: TIME, COST, AND COMPLEXITY OF REGISTRATION
                               5.8.2.1.2 Canada
                                               TABLE 9 CANADA: MEDICAL DEVICE CLASSIFICATION
                                               TABLE 10 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION
                    5.8.2.2 Europe
                    5.8.2.3 Asia Pacific
                               5.8.2.3.1 Japan
                               5.8.2.3.2 China
                                               TABLE 11 CHINA: MEDICAL DEVICE CLASSIFICATION
                               5.8.2.3.3 India
    5.9 PATENT ANALYSIS 
           5.9.1 PATENT PUBLICATION TRENDS FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE PRODUCTS
                    FIGURE 23 PATENT PUBLICATION TRENDS (JANUARY 2011–AUGUST 2023)
           5.9.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
                    FIGURE 24 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE PATENTS (JANUARY 2011–AUGUST 2023)
                    FIGURE 25 TOP APPLICANTS FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE PATENTS (COUNTRY/REGION) (JANUARY 2011–AUGUST 2023)
                    TABLE 12 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: LIST OF PATENTS (2020–2023)
    5.10 KEY CONFERENCES & EVENTS IN 2023–2024 
           TABLE 13 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DETAILED LIST OF CONFERENCES & EVENTS IN 2023–2024
    5.11 TRADE ANALYSIS 
           5.11.1 TRADE ANALYSIS FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE DIAGNOSTIC SYSTEMS
                     FIGURE 26 IMPORTS OF PRODUCTS UNDER HSN CODE: 90278090, BY COUNTRY,  2022 (USD THOUSAND)
                     FIGURE 27 EXPORTS OF PRODUCTS UNDER HSN CODE: 90278090, BY COUNTRY,  2022 (USD THOUSAND)
    5.12 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS
                     TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS (%)
           5.12.2 BUYING CRITERIA
                     FIGURE 29 KEY BUYING CRITERIA FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS
                     TABLE 15 KEY BUYING CRITERIA FOR ANTIMICROBIAL RESISTANCE SURVEILLANCE END USERS
 
6 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET,  BY SOLUTION (Page No. - 75)
    6.1 INTRODUCTION 
          TABLE 16 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION,  2021–2028 (USD MILLION)
    6.2 DIAGNOSTIC KITS 
           6.2.1 RISING AWARENESS OF AMR TO DRIVE MARKET GROWTH
                    TABLE 17 DIAGNOSTIC KITS OFFERED BY KEY PLAYERS
                    TABLE 18 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR DIAGNOSTIC KITS,  BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 DIAGNOSTIC SYSTEMS 
           6.3.1 GROWING THREAT OF ANTIBIOTIC RESISTANCE TO ACCELERATE MARKET GROWTH
                    TABLE 19 DIAGNOSTIC SYSTEMS OFFERED BY KEY PLAYERS
                    TABLE 20 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR DIAGNOSTIC SYSTEMS,  BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 SURVEILLANCE & ANALYTICS SOFTWARE 
           6.4.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH
                    TABLE 21 SURVEILLANCE & ANALYTICS SOFTWARE OFFERED BY KEY PLAYERS
                    TABLE 22 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR SURVEILLANCE & ANALYTICS SOFTWARE, BY COUNTRY, 2021–2028 (USD MILLION)
    6.5 OTHER SOLUTIONS 
          TABLE 23 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR OTHER SOLUTIONS,  BY COUNTRY, 2021–2028 (USD MILLION)
 
7 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET,  BY APPLICATION (Page No. - 82)
    7.1 INTRODUCTION 
          TABLE 24 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
    7.2 CLINICAL DIAGNOSTICS 
           7.2.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH
                    TABLE 25 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR CLINICAL DIAGNOSTICS,  BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 PUBLIC HEALTH SURVEILLANCE 
           7.3.1 GOVERNMENT INITIATIVES TO ACCELERATE MARKET GROWTH
                    TABLE 26 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR PUBLIC HEALTH SURVEILLANCE, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 OTHER APPLICATIONS 
          TABLE 27 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR OTHER APPLICATIONS,  BY COUNTRY, 2021–2028 (USD MILLION)
 
8 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET,  BY END USER (Page No. - 87)
    8.1 INTRODUCTION 
          TABLE 28 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER,  2021–2028 (USD MILLION)
    8.2 HOSPITALS & CLINICS 
           8.2.1 HIGH PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
                    TABLE 29 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR HOSPITALS & CLINICS,  BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 RESEARCH & ACADEMIC INSTITUTES 
           8.3.1 GROWING RESEARCH GRANTS AND FUNDING TO ACCELERATE MARKET GROWTH
                    TABLE 30 FUNDING BY DEPARTMENT OF HEALTH AND SOCIAL CARE (UK) FOR ANTIMICROBIAL RESISTANCE STUDIES, 2020
                    TABLE 31 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 OTHER END USERS 
          TABLE 32 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET FOR OTHER END USERS,  BY COUNTRY, 2021–2028 (USD MILLION)
 
9 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY REGION (Page No. - 93)
    9.1 INTRODUCTION 
          TABLE 33 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY REGION,  2021–2028 (USD MILLION)
    9.2 NORTH AMERICA 
          FIGURE 30 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SNAPSHOT
          TABLE 34 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 35 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION)
          TABLE 36 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 37 NORTH AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.2.1 US
                    9.2.1.1 US to dominate North American market during forecast period
                                TABLE 38 US: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION,  2021–2028 (USD MILLION)
                                TABLE 39 US: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 40 US: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Favorable government initiatives to drive growth during forecast period
                                TABLE 41 CANADA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION,  2021–2028 (USD MILLION)
                                TABLE 42 CANADA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 43 CANADA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.2.3 NORTH AMERICA: RECESSION IMPACT
    9.3 EUROPE 
          TABLE 44 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 45 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION,  2021–2028 (USD MILLION)
          TABLE 46 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
          TABLE 47 EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Germany to dominate European market during forecast period
                                TABLE 48 GERMANY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION,  2021–2028 (USD MILLION)
                                TABLE 49 GERMANY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 50 GERMANY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.3.2 UK
                    9.3.2.1 Significant prevalence of infectious diseases coupled with increasing awareness to drive market growth
                                TABLE 51 UK: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION,  2021–2028 (USD MILLION)
                                TABLE 52 UK: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 53 UK: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 Supportive government policies and easy accessibility to healthcare services to fuel growth
                                TABLE 54 FRANCE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION,  2021–2028 (USD MILLION)
                                TABLE 55 FRANCE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 56 FRANCE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Increasing R&D investments by pharmaceutical companies to propel demand
                                TABLE 57 ITALY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION,  2021–2028 (USD MILLION)
                                TABLE 58 ITALY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 59 ITALY: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Rising geriatric population to drive market growth
                                TABLE 60 SPAIN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION,  2021–2028 (USD MILLION)
                                TABLE 61 SPAIN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 62 SPAIN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 63 REST OF EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION)
                    TABLE 64 REST OF EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
                    TABLE 65 REST OF EUROPE: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.7 EUROPE: RECESSION IMPACT
    9.4 ASIA PACIFIC 
          FIGURE 31 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET SNAPSHOT
          TABLE 66 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 67 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION)
          TABLE 68 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 69 ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.1 JAPAN
                    9.4.1.1 Growing geriatric population to drive market
                                TABLE 70 JAPAN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION,  2021–2028 (USD MILLION)
                                TABLE 71 JAPAN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 72 JAPAN: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.4.2 CHINA
                    9.4.2.1 Favorable government regulations and heavy burden of infectious diseases to drive market growth
                                TABLE 73 INCIDENCE OF INFECTIOUS DISEASES IN CHINA, 2020
                                TABLE 74 CHINA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION,  2021–2028 (USD MILLION)
                                TABLE 75 CHINA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 76 CHINA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Growing initiatives for clinical diagnosis by government and major players to drive market growth
                                TABLE 77 INDIA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION,  2021–2028 (USD MILLION)
                                TABLE 78 INDIA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION,  2021–2028 (USD MILLION)
                                TABLE 79 INDIA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER,  2021–2028 (USD MILLION)
           9.4.4 REST OF ASIA PACIFIC
                    TABLE 80 REST OF ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET,  BY SOLUTION, 2021–2028 (USD MILLION)
                    TABLE 81 REST OF ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
                    TABLE 82 REST OF ASIA PACIFIC: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET,  BY END USER, 2021–2028 (USD MILLION)
           9.4.5 ASIA PACIFIC: RECESSION IMPACT
    9.5 LATIN AMERICA 
           9.5.1 GROWING ECONOMIC DEVELOPMENT TO DRIVE MARKET GROWTH
           9.5.2 LATIN AMERICA: RECESSION IMPACT
                    TABLE 83 LATIN AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY SOLUTION, 2021–2028 (USD MILLION)
                    TABLE 84 LATIN AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                    TABLE 85 LATIN AMERICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET, BY END USER, 2021–2028 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA 
           9.6.1 GROWING INCIDENCE OF INFECTIOUS DISEASES AND LARGE PATIENT POOL TO DRIVE MARKET GROWTH
           9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
                    TABLE 86 MIDDLE EAST & AFRICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET,  BY SOLUTION, 2021–2028 (USD MILLION)
                    TABLE 87 MIDDLE EAST & AFRICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET,  BY APPLICATION, 2021–2028 (USD MILLION)
                    TABLE 88 MIDDLE EAST & AFRICA: ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET,  BY END USER, 2021–2028 (USD MILLION)
 
10 COMPETITIVE LANDSCAPE (Page No. - 130)
     10.1 INTRODUCTION 
     10.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             TABLE 89 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET
     10.3 REVENUE SHARE ANALYSIS 
             FIGURE 32 REVENUE ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET (2018–2022)
     10.4 MARKET SHARE ANALYSIS 
             FIGURE 33 MARKET SHARE ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET (2022)
     10.5 COMPANY EVALUATION MATRIX FOR MAJOR PLAYERS (2022) 
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
                        FIGURE 34 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
             10.5.5 COMPANY FOOTPRINT
                        TABLE 90 COMPANY FOOTPRINT ANALYSIS, BY SOLUTION
                        TABLE 91 COMPANY FOOTPRINT ANALYSIS, BY APPLICATION
                        TABLE 92 COMPANY FOOTPRINT ANALYSIS, BY END USER
                        TABLE 93 COMPANY FOOTPRINT ANALYSIS, BY REGION
     10.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022) 
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 RESPONSIVE COMPANIES
             10.6.3 DYNAMIC COMPANIES
             10.6.4 STARTING BLOCKS
                        FIGURE 35 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: COMPANY EVALUATION MATRIX FOR SMES/START-UPS, 2022
             10.6.5 COMPETITIVE BENCHMARKING
                        TABLE 94 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: COMPANY FOOTPRINT OF KEY PLAYERS
     10.7 COMPETITIVE SCENARIO 
             10.7.1 PRODUCT LAUNCHES
                        TABLE 95 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2020–SEPTEMBER 2023
             10.7.2 DEALS
                        TABLE 96 ANTIMICROBIAL RESISTANCE SURVEILLANCE MARKET: DEALS,  JANUARY 2020–SEPTEMBER 2023
 
11 COMPANY PROFILES (Page No. - 145)
     11.1 KEY PLAYERS 
(Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses & Competitive threats)*
             11.1.1 BIOMÉRIEUX SA
                        TABLE 97 BIOMÉRIEUX SA: BUSINESS OVERVIEW
                        FIGURE 36 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2022)
             11.1.2 THERMO FISHER SCIENTIFIC INC.
                        TABLE 98 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             11.1.3 BECTON, DICKINSON AND COMPANY
                        TABLE 99 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
             11.1.4 DANAHER CORPORATION
                        TABLE 100 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
             11.1.5 BIO-RAD LABORATORIES, INC.
                        TABLE 101 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 40 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
             11.1.6 LUMINEX CORPORATION
                        TABLE 102 LUMINEX CORPORATION: BUSINESS OVERVIEW
                        FIGURE 41 LUMINEX CORPORATION: COMPANY SNAPSHOT (2022)
             11.1.7 BRUKER CORPORATION
                        TABLE 103 BRUKER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 42 BRUKER CORPORATION: COMPANY SNAPSHOT (2022)
             11.1.8 ROCHE DIAGNOSTICS (A DIVISION OF F-HOFFMAN-LA ROCHE LTD.)
                        TABLE 104 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW
                        FIGURE 43 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2022)
             11.1.9 T2 BIOSYSTEMS, INC.
                        TABLE 105 T2 BIOSYSTEMS, INC.: BUSINESS OVERVIEW
                        FIGURE 44 T2 BIOSYSTEMS, INC.: COMPANY SNAPSHOT (2022)
             11.1.10 MERCK KGAA
                        TABLE 106 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2022)
             11.1.11 ACCELERATE DIAGNOSTICS, INC.
                        TABLE 107 ACCELERATE DIAGNOSTICS, INC.: BUSINESS OVERVIEW
                        FIGURE 46 ACCELERATE DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)
             11.1.12 BIOANALYSE
                        TABLE 108 BIOANALYSE: BUSINESS OVERVIEW
             11.1.13 HIMEDIA LABORATORIES
                        TABLE 109 HIMEDIA LABORATORIES: BUSINESS OVERVIEW
             11.1.14 LIOFILCHEM S.R.L.
                        TABLE 110 LIOFILCHEM S.R.L.: BUSINESS OVERVIEW
             11.1.15 ALIFAX S.R.L.
                        TABLE 111 ALIFAX S.R.L.: BUSINESS OVERVIEW
             11.1.16 WOLTERS KLUWER N.V.
                        TABLE 112 WOLTERS KLUWER N.V.: BUSINESS OVERVIEW
                        FIGURE 47 WOLTERS KLUWER N.V.: COMPANY SNAPSHOT (2022)
             11.1.17 OPGEN, INC.
                        TABLE 113 OPGEN, INC.: BUSINESS OVERVIEW
                        FIGURE 48 OPGEN, INC.: COMPANY SNAPSHOT (2022)
             11.1.18 CREATIVE DIAGNOSTICS
                        TABLE 114 CREATIVE DIAGNOSTICS: BUSINESS OVERVIEW
             11.1.19 SYNBIOSIS
                        TABLE 115 SYNBIOSIS: BUSINESS OVERVIEW
     11.2 OTHER PLAYERS 
             11.2.1 ZHUHAI DL BIOTECH CO., LTD.
             11.2.2 ELITECHGROUP
             11.2.3 MAST GROUP LTD.
             11.2.4 CONDALAB
             11.2.5 GENEFLUIDICS, INC.
             11.2.6 MP BIOMEDICALS
 
*Details on Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses & Competitive threats might not be captured in case of unlisted companies.
 
12 APPENDIX (Page No. - 198)
     12.1 DISCUSSION GUIDE 
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     12.3 CUSTOMIZATION OPTIONS 
     12.4 RELATED REPORTS 
     12.5 AUTHOR DETAILS 

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the use of comprehensive secondary sources; directories and databases such as D&B, Bloomberg Business, and Factiva; and white papers, annual reports, and companies’ house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of the antimicrobial resistance surveillance market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, technology perspectives, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side and demand side are detailed below. Industry experts such as CEOs, presidents, vice presidents, directors, marketing directors, marketing managers, and related executives from various key companies and organizations in the antimicrobial resistance surveillance industry were interviewed to obtain and verify both the qualitative and quantitative aspects of this research study. A robust primary research methodology has been adopted to validate the contents of the report and fill in the gaps.

A breakdown of the primary respondents is provided below:

Antimicrobial Resistance Surveillance Market Size, and Share

*Others include sales managers, marketing managers, and product managers.

Note: Tiers are defined based on a company’s total revenue, as of 2022: Tier 1 = >USD 5 billion, Tier 2 = USD 1 billion to USD 5 billion, and Tier 3 = <USD 1 billion.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME

DESIGNATION

Danaher

Assistant Manager Sales

Luminex Corporation

Assistant Project Manager

Qiagen

Business Development Manager

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (revenue share analysis) primary interviews, and top-down approach (assessment of Individual shares of each solution, application, and end-user segment).

Antimicrobial Resistance Surveillance Market Size: Revenue Share Analysis

Antimicrobial Market Size: Bottom up Approach

  • For estimating the size of the global Antimicrobial resistance surveillance market, the country-level market revenues were obtained from secondary sources and through extensive primary interviews.
  • Country-level markets for the US and Canada were added to arrive at the market size for North America. Similarly, country-level markets for Germany, France, the UK, Spain, Italy, and the Rest of Europe were added to arrive at the market size for Europe, and the market sizes of Japan, China, India, and the Rest of Asia Pacific were added to arrive at the market size of the Asia Pacific.
  • The markets for North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa were added to arrive at the global market.
  • The total market derived through the bottom-up approach was again validated through secondary sources and primary interviews.

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation, and market breakdown procedures were employed, wherever applicable.

Antimicrobial Resistance Surveillance Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Antimicrobial Resistance Surveillance Market Size, and Share

Market Definition

Antimicrobial resistance (AMR) surveillance is a systematic process of monitoring and tracking the ability of microorganisms (such as bacteria, viruses, fungi) to resist the effects of antimicrobial drugs, including antibiotics, antivirals, and antifungal medications.

Key Stakeholders

  • Distributors, Suppliers, and Commercial Service Providers
  • Healthcare Service Providers
  • Manufacturers of Pharmaceutical Products
  • Clinical Research Organizations (CROs)
  • Clinical Testing Laboratories
  • Blood Culture Media Manufacturers
  • Food & Beverage Manufacturing Companies
  • Environmental Monitoring Committees
  • Manufacturers of Environmental Monitoring Products
  • National & Regional Pollution Control Boards and Organizations
  • Research Laboratories and Academic Institutes
  • Market Research and Consulting Firms

Objectives of the Study

  • To define, describe, segment, and forecast the antimicrobial resistance surveillance market by solution, application, end user, and region
  • To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall antimicrobial resistance surveillance market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To estimate and forecast the size of the antimicrobial resistance surveillance market in five main regions (along with their respective key countries), namely, North America, Europe, the Asia Pacific, Latin America, and Middle East Africa.
  • To profile the key players and analyze their market shares and core competencies3
  • To track and analyze competitive developments such as product launches, agreements, partnership, and acquisitions in the global antimicrobial resistance surveillance market
  • To benchmark players within the antimicrobial resistance surveillance market using the competitive leadership mapping framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolio of each company

Company Information

  • Detailed analysis and profiling of additional market players (up to five)
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
BT 8787
Published ON
Sep, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Antimicrobial Resistance Surveillance Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status
Website Feedback